OSEO

OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies for cancer and autoimmune diseases. The company's portfolio includes Tedopi, a neoepitope-based vaccine in Phase 3 for non-small cell lung cancer, and several high-potential antibodies targeting myeloid checkpoints and pro-resolutive pathways. OSE leverages its proprietary platforms to create first-in-class therapies, often in collaboration with major pharmaceutical partners like AbbVie, Boehringer Ingelheim, and Servier. Headquartered in France, the company is a key player in the European immunotherapy landscape, aiming to address significant unmet medical needs in oncology and immunology.